Mathew Thomas
Publications by Year
Research Areas
Chronic Myeloid Leukemia Treatments, Chronic Lymphocytic Leukemia Research, Click Chemistry and Applications, Eosinophilic Disorders and Syndromes, Lung Cancer Treatments and Mutations
Most-Cited Works
- → AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance(2009)1,234 cited
- → Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase(2016)396 cited
- → Structural Mechanism of the Pan‐BCR‐ABL Inhibitor Ponatinib (AP24534): Lessons for Overcoming Kinase Inhibitor Resistance(2010)282 cited
- → Abstract 3623: Efficacy and pharmacodynamic analysis of AP26113, a potent and selective orally active inhibitor of Anaplastic Lymphoma Kinase (ALK)(2010)27 cited
- → Discovery of 5-(arenethynyl) hetero-monocyclic derivatives as potent inhibitors of BCR–ABL including the T315I gatekeeper mutant(2011)18 cited
- Abstract #3738: Discovery of potent and selective orally active inhibitors of anaplastic lymphoma kinase (ALK)(2009)
- → Orally Active Inhibitors of the Imatinib Resistant Bcr-Abl Mutant T315I.(2006)10 cited
- → Abstract 2671: Structural analysis of the inhibitory mechanism of AP24534, a pan-BCR-ABL inhibitor overriding the T315I gatekeeper mutation(2010)
- → Crystal structure of the kinase domain of human c-KIT in complex with a type-II inhibitor bearing an acrylamide(2020)
- → Crystal structure of the KDR (VEGFR2) kinase domain in complex with a type-II inhibitor(2020)